Neuronal ablation of Prnp triggers chronic demyelinating polyneuropathy (CDP) 1 , suggesting that Schwann cells bear a PrP C receptor. We therefore assessed the binding of full-length PrP C (recPrP, residues 23-231), the flexible tail (FT; residues 23-110), or its refolded globular domain (GD; residues 121-231), to primary Schwann cell (PSC) cultures from Prnp ZH1/ZH1 sciatic nerves 3 using POM1 and POM2 antibodies against epitopes of PrP C (ref. 4). Both recPrP and FT, but not GD, were found to stain PSCs (Extended Data Fig. 1a) .
Neuronal ablation of Prnp triggers chronic demyelinating polyneuropathy (CDP) 1 , suggesting that Schwann cells bear a PrP C receptor. We therefore assessed the binding of full-length PrP C (recPrP, residues 23-231), the flexible tail (FT; residues 23-110), or its refolded globular domain (GD; residues 121-231), to primary Schwann cell (PSC) cultures from Prnp ZH1/ZH1 sciatic nerves 3 using POM1 and POM2 antibodies against epitopes of PrP C (ref. 4). Both recPrP and FT, but not GD, were found to stain PSCs (Extended Data Fig. 1a) .
Using transcription activator-like effector nucleases, we generated a Prnp-ablated subclone (termed SW10 ∆PrP ) of the SW10 Schwann cell line (Extended Data Fig. 1b, c) . Again, recPrP and FT, but not GD, adhered to SW10 ∆PrP cells (Fig. 1a and Extended Data Fig. 1d , e). Neither recPrP nor FT adhered to the Prnp −/− hippocampal cell line HpL 5 (Extended Data Fig. 1f ), suggesting that binding was specific to Schwann cells. We next measured the binding of synthetic PrP-derived peptides (2 μ M, 20 min) to SW10 ∆PrP cells (Fig. 1b) . FT , but neither FT 39-66 nor any of the C-proximal peptides (Extended Data Table 1) , showed binding to SW10 ∆PrP cells (Fig. 1c) , suggesting that residues 23-38 are essential for this interaction.
We treated SW10 cells with trypsin (2.5% w/v, 10 min) to degrade membrane-resident proteins. Following trypsin inactivation, we added non-trypsinized SW10 cells labelled with the cell-tracking dye Deep Red. Haemagglutinin (HA)-tagged FT (2 μ M) was added to the cells, and binding was monitored with anti-HA antibodies. FT bound to 51% of the non-trypsinized cells and 5% of the trypsinized cells (Extended Data Fig. 1g ), suggesting that there is a surface FT receptor on Schwann cells. Cytofluorimetry revealed no altered binding of HA-tagged FT to SW10 cells treated with phosphoinositol phospholipase C (PI-PLC, 30 min at 37 °C), indicating that binding did not require glycophosphatidylinositol (GPI)-anchored surface proteins, whereas binding of POM2 was greatly reduced, indicating that PrP C had been stripped from cell surfaces (Extended Data Fig. 1h ).
Might the FT alter cAMP signalling in Schwann cells? Sciatic nerves taken from Prnp
ZH1/ZH1 and wild-type mice at 4 days of age showed similar cAMP levels (Extended Data FT [95] [96] [97] [98] [99] [100] [101] [102] [103] [104] [105] [106] [107] [108] [109] [110] FT FT FT PBS FT FT FT 51-94 C . a, Prnp-ablated SW10 cells (SW10 ∆PrP ) were exposed to recombinant PrP C (recPrP), FT, or GD (ligand). PrP C and FT, but not GD, adhered to Schwann cells (red: POM1 and POM2 antibodies; grey: DAPI). p75 NGFR antibodies identified Schwann cells. Scale bars, 26 μ m. b, FT-derived peptides and PrP C domains. CC1 and CC2, charge clusters 1 and 2; OR, octapeptide repeats. Peptides are colour-coded as in c. c, SW10 ∆PrP cells were exposed to FT-derived peptides (2 μ M, 20 min) carrying a C-terminal HA tag. Flow cytometry showed strong binding by peptide FT 
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taken from 4-week-old Prnp ZH1/ZH1 mice showed a trend towards decreased cAMP levels (Extended Data Fig. 2b ). When taken from Prnp ZH1/ZH1 mice at 12-16 weeks, when CDP is incipient 1 , sciatic nerves exhibited significantly lower cAMP levels than those taken from wild-type mice ( Fig. 1d ; P = 0.0115). Sciatic nerve lysates from strictly isogenic C57BL/6J Prnp ZH3/ZH3 mice 6 (10-16 weeks old) also displayed significantly lower levels of cAMP than did those from wild-type mice (Extended Data Fig. 2c ).
Sciatic nerves from 12-16-week-old tgNSE-PrP mice, which express PrP C in neurons, showed cAMP levels similar to those of wild-type mice, whereas sciatic nerves from tgMBP-PrP mice, which express PrP C in Schwann cells and suffer from CDP 1 , showed lower cAMP levels (Extended Data Fig. 2d) Fig. 3a, b) . Exposure to conditioned medium from HEK PrP cells, but not from HEK empty cells, raised cAMP levels in PSC cultures generated from Prnp ZH1/ZH1 mice (Fig. 2b) . Spent medium from PSC cultures and sciatic nerves from 10-week-old C57BL/6 mice did not contain any FT, suggesting that little FT is released by Schwann cells (Extended Data Fig. 3c, d ).
To find out whether the FT contains motifs responsible for inducing the cAMP response, we treated SW10 ∆PrP cells with the same synthetic peptides used previously to assess binding to Schwann cells. Peptide FT induced a cAMP response, whereas FT 34-69 and all C-proximal peptides were inactive (Fig. 2c) . These results suggest that residues 23-33, which contain the lysine-rich charge cluster 1 (CC1), represent the biologically active region of the FT. To test this prediction, we incubated FT with monovalent recombinant phage-derived miniantibodies recognizing the CC1 (Fab3) or octapeptide repeats (Fab71) of PrP C . Preincubation with Fab3, but not with Fab71, significantly quenched the ability of FT to induce an increase in cAMP in SW10 ∆PrP cells (Fig. 2d) .
Peripheral nervous system myelination is controlled by Gpr126, an adhesion GPCR expressed by Schwann cells 7, 8 . We therefore generated HEK293T cells stably overexpressing human Gpr126 or, as controls, Gpr124 or Gpr176 (denoted HEK Gpr126 , HEK Gpr124 , and HEK Gpr176 , respectively) with a C-terminal V5 epitope tag 9 (Extended Data Fig. 3e ). Flow cytometry revealed that FT bound to HEK Gpr126 cells but not to HEK Gpr124 or HEK Gpr176 cells (Extended Data Fig. 3f, g ). Moreover, exposure to FT (20 min, ≥ 500 nM) increased cAMP in HEK Gpr126 cells but not in HEK Gpr124 or HEK Gpr176 cells (Fig. 3a) . We then treated HEK293T, HEK
Gpr124
, and HEK Gpr126 cells with recombinant FT or GD (20 min, 2 μ M). FT was detected only in lysates from HEK Gpr126 cells immunoprecipitated with anti-V5 antibodies, and GD was not detected in lysates from any of the cells (Extended Data Fig. 4a) .
Next, we generated clonal SW10 cells devoid of endogenous Gpr126 (designated SW10 ∆Gpr126 ). When treated with FT , SW10 (but not SW10 ∆Gpr126 ) cells reacted with increased cAMP levels. A modified − → FT 23 50 K A peptide (with lysine residues replaced with alanines) was ineffective in binding cells and inducing cAMP (Fig. 3b) . We then treated SW10 ∆Gpr126 cells transfected with human Gpr126, Gpr124, Gpr176 or Gpr56 with FT . Only Gpr126-transfected cells showed a cAMP response (Extended Data Fig. 4b ) similar to that of naive SW10 We then administered FT (20 min, 2 μ M) to HEK Gpr126 cells and HEK293(H) cells (a clonal variant of HEK293T cells with superior growth and transfection efficiencies) transfected with plasmids encoding human Gpr56, Gpr64, Gpr133, or Gpr97. Only Gpr126-expressing cells showed a cAMP response (Extended Data Fig. 4f ). The magnitude of the cAMP response was not enhanced by increasing the amount of transfected plasmid, suggesting that other signalling components became limiting (Extended Data Fig. 5a ). There was no cAMP induction in Prnp ZH1/ZH1 cerebellar granule neuronal cultures treated with FT Egr2 (also known as Krox-20) controls the expression of myelin genes and has been implicated in myelin maintenance 12 . Egr2 expression was decreased in sciatic nerves from 13-week-old Prnp ZH3/ZH3 mice (P < 0.05; Fig. 3c ), and recombinant FT (2 μ M, 24 h) activated Egr2-dependent luciferase expression in SW10 cells (Extended Data Fig. 5e ). Similarly, Egr2 transcription was upregulated in primary Schwann cells treated with recombinant FT (2 μ M, 1 h) (Extended Data Fig. 5f ). Also, Akt phosphorylation increased 5 min after treatment with recombinant FT (2 μ M) and peaked at 10 min in SW10 ∆PrP but not SW10 ∆Gpr126 cells (Extended Data Fig. 5g ). The integrity of SW10 cells and their subclones was confirmed by the expression of myelin genes (Extended Data Fig. 6a ).
We identified two regions of similarity between FT (KKRPKPG and QGSPG) and the Gpr126 ligand, type-IV collagen (Col4) 2 (GPRGKPG and QGSPG; Fig. 4a ). Replacement of the conserved cationic residues with alanines (KKRPKPG → AAAPAPG), but not other substitutions, abrogated cAMP induction in SW10 ∆PrP cells (Fig. 4b) ; treatment with FT [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] (2 μ M, 20 min), which contains KKRPKPG, sufficed to induce cAMP in SW10 ∆PrP but not in SW10 ∆Gpr126 cells (Fig. 4c) . We next generated murine PrP C mutants containing alanine substitutions in either of the two conserved motifs. After transient transfection, both mutants were highly expressed by HEK293T cells (Extended Data Fig. 6b ), and cleaved FT was recovered in the medium (Extended Data  Fig. 6c ). When applied to SW10 ∆PrP cells, conditioned medium from HEK293T cells expressing wild-type or QGSPG-mutated PrP In zebrafish, Gpr126 controls myelination; however, Prnp −/− mice have no obvious myelination defects but develop a late-onset peripheral neuropathy with demyelination, onion bulb formation ( . When applied to gpr126 st63 zebrafish larvae at 50-55 h post-fertilization (hpf), FT (20 μ M) increased Mbp expression in the PLLn at 5 days post-fertilization (dpf) compared to DMSO-treated larvae ( Fig. 5c, d ; P < 0.05). We also treated gpr126 st49 larvae, which encode a truncated Gpr126 incapable of G s signalling 8, 16 . Mbp was barely detectable in both FT (Fig. 5g ). Here we report, to our knowledge, the first molecular elucidation of a phenotype caused by PrP C deficiency. While Gpr126 is crucial for peripheral nerve myelination during development, the late-onset phenotype of Prnp-ablated mice suggests that it has additional roles in myelin maintenance. Gpr126 −/− mice exhibit drastic hypomyelination, but the Prnp −/− phenotype is relatively mild and late-onset, akin to peripheral neuropathies, whose prevalence is 2.4% generally and 8% among the aged K A ), but not of QGSPG, abrogated cAMP induction. c, SW10 ∆PrP and SW10 ∆Gpr126 cells were exposed (2 μ M, 20 min) to the synthetic peptides FT , FT [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] or SFT [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] (peptide containing scrambled amino acid sequence of FT [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] ). FT and FT [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] induced cAMP in SW10 ∆PrP cells but not SW10 ∆Gpr126 cells. Error bars show s.e.m. Panels depict independent triplicates; unpaired Student's t-test was used for analysis. * * P < 0.01; * * * P < 0.001. 
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RESEARCH peptides suggest that soluble ligands may be beneficial in diseases caused by hypomorphic Gpr126 mutations
19
, and perhaps also in other hereditary motor-sensory neuropathies.
A moderately conserved homology region between PrP C and Col4 proved essential to the biological activity of both proteins, whereas laminin-211 might activate Gpr126 through different mechanisms. Although Gpr126 is not expressed in the central nervous system, certain mutants of PrP C cause myelin pathology in vivo
20
. This observation raises the question of whether inappropriate GPCR activation may play a role in prion diseases within the CNS.
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Reviewer Information Nature thanks D. Pleasure and the other anonymous reviewer(s) for their contribution to the peer review of this work. . Mice of both genders were used for experiments unless specified. Archival tissues from previous studies 1, 6 were also analysed in the current study. No statistical methods were used to predetermine sample size. The experiments were not randomized and the investigators were not blinded to allocation during experiments and outcome assessment except where stated. Primary Schwann cell culture. Sciatic nerves from postnatal day 2-5 were dissected using microsurgical techniques. Nerves were dissociated in serum-free DMEM supplemented with 0.05% collagenase IV (Worthington) for 1 h in the incubator. Sciatic nerves were mechanically dissociated using fire-polished Pasteur pipettes. Cells were filtered in a 40-μ M cell strainer and washed in Schwann cell culture medium (DMEM, Pen-Strep, Glutamax, FBS 10%) by centrifugation at 300g for 10 min. Resuspended cells were plated on 3.5 cm Petri dishes previously coated with poly-l-lysine 0.01% (w/v) and laminin (1 mg/ml). Laminin (Cat. No: L2020; from Engelbreth-Holm-Swarm murine sarcoma basement membrane) and poly-l-lysine were obtained from Sigma-Aldrich. Purification of recombinant proteins. Full-length recombinant PrP (recPrP, residues 23-231) and globular domain (GD, residues 121-231) were purified as previously described [21] [22] [23] . The generation of the GST fusion FT-PrP expression vector (pGEX-KG FT-PrP) was described previously; a modified purification protocol was used 24 . The FT-PrP expression vector was transformed into BL21 (DE3) strain of Escherichia coli (Invitrogen). Bacteria were grown in Luria-Bertani medium to an OD of 0.6, and the expression of the fusion protein was induced with 0.5 mM isopropyl-1-thio-β -d-galactopyranoside (AppliChem). Cells were then grown for another 4 h at 37 °C and 100 rpm shaking. Cells were pelleted at 5,000g for 20 min at 4 °C (Sorvall centrifuge, DuPont). The pellet was resuspended on ice in lysis buffer (phosphate-buffered saline supplemented with complete protease inhibitors (EDTA-free, Roche), phenylmethyl sulfonyl fluoride (Sigma) and 150 μ M lysozyme (Sigma)) and incubated on ice for 30 min. Triton-X 100 (1%), MgCl 2 (10 mM) and DNase I (5 μ g/ml, Roche) were added, and the lysate was incubated on ice for 30 min. The lysate was than centrifuged for 20 min at 10,000g at 4 °C. Glutathione sepharose beads were washed with PBS and incubated with the cell lysate for 1 h at 4 °C on a rotating device. Beads were packed into a column and washed with PBS until a stable baseline was reached as monitored by absorbance at A 280 using an ÄKTAprime (GE healthcare). The fusion protein was cleaved on the beads with 5 U/ml Thrombin (GE Healthcare) for 1 h at room temperature under agitation. For thrombin removal, benzamidine sepharose beads were added and incubated for 1 h at 4 °C on a rotating wheel. Protein preparations were analysed by 12% NuPAGE gels followed by Coomassie-or silver-staining. To achieve a higher purity of the protein, we next applied the protein to a sulfopropyl (SP) sepharose column equilibrated with 50 mM Tris-HCl buffer, pH 8.5. Elution was performed with a linear NaCl gradient of 0-1,000 mM. Fractions containing the protein were collected and concentrated (AMICON; MWCO 3500). The protein was then injected in 500 μ l portions into a size-exclusion chromatography system (TSK-GEL G2000SW XL column (Tosoh Bioscience)) and eluted with a linear gradient using PBS. Pure fractions were combined, concentrated and stored at − 20 °C. The purity of FT-PrP was > 95-98% as judged by a silver-stained 12% NuPAGE gel. Cell culture. SW10 cells and clones derived from them were all grown in DMEM medium supplemented with 10% fetal bovine serum (FBS), penicillin-streptomycin and Glutamax (all obtained from Invitrogen). HEK293T cells, its clonal variant HEK293(H) cells and clones derived therefrom overexpressing various GPCRs were grown in DMEM-F12 medium supplemented with 10% FCS, penicillinstreptomycin and Glutamax (all obtained from Invitrogen). All cell lines were regularly monitored for mycoplasma contamination. The authenticity of SW10 and its derivatives was established by monitoring the expression of Schwann-cell specific markers (Extended Data Fig. 6a ). Human Gpr126 (NM_020455), Gpr124, Gpr64, Gpr56, Gpr133, Gpr56 and Gpr176 expression plasmids (pCGpr126-V5, pCGpr124-V5, pCGpr65-V5, pCGpr56-V5, pCGpr133-V5, pCGpr56-V5 and pCGpr176-V5) were generated by PCR amplification of the respective cDNA followed by TOPO cloning into the pCDNA3.1/V5-His-TOPO vector. The cDNA was in frame with the V5 tag (sequence: GKPIPNPLLGLDST) at the C terminus. HEK GPR126 and HEK GPR176 cells were generated by transfecting 1 μ g of plasmid into one well of a subconfluent 6-well plate using 3 μ l Fugene (Roche) according to the manufacturer's protocol. Twenty-four hours after transfection, cells were transferred to a 10-cm dish and grown in selective medium containing 0.4 mg/ml G418 (Invitrogen) until emergence of resistant colonies. A limiting dilution was carried out to obtain clonal lines. Membrane expression of the transgene was assessed in the selected clones by confocal microscopy using 1:100 diluted anti-V5 antibody (Invitrogen) and the Cytofix/Cytoperm kit (Pharmingen Cat. Nr. 554714), according to the manufacturer's protocol. Cerebellar granule neuronal culture. Cerebellar granule neurons were generated from 7-8-day-old Prnp ZH1/ZH1 mice as described previously 25 . Cultures were plated at 350,000 cells per cm 2 in Basal Medium Eagle (BME) (Invitrogen) with 10% (v/v) FCS and maintained at 37 °C in 5% CO 2 . Plasmids and transfections. pCDNA-PrP C was generated by cloning murine PrP C into pCDNA3.1 vector as described previously 26 . A site-specific mutagenesis kit (Stratagene) was used to induce alanine substitutions of QPSPG and KKRPK domains in PrP C . Primers used for generating the Ala-QPSPG plasmid were: forward, GTG GAA GCC GGT ATC CCG GGG CGG CAG CCG CTG CAG GCA ACC GTT ACC C; reverse, GGG TAA CGG TTG CCT GCA GCG GCT GCC GCC CCG GGA TAC CGG CTT CCA C. Primers for Ala-KKRPK were: forward, CTA TGT GGA CTG ATG TCG GCC TCT GCG CAG CGG CGC CAG CGC CTG GAG GGT GGA ACA CCG; reverse, CGG TGT TCC ACC CTC CAG GCG CTG GCG CCG CTG CGC AGA GGC CGA CAT CAG TCC ACA TAG. Transfections were performed with Lipofectamine 2000 (Invitrogen) according to the manufacturer's protocol. 3 μ g of DNA was used per well of a 6-well plate. Cells were washed 24 h after transfection using PBS, and fresh medium was added to the cells.
Immunoprecipitation. HEK293T and HEK
GPR126 cells growing in T75 flasks at 50% density were treated with recombinant FT or GD (2 μ M, 20 min). Cells were washed twice in PBS and lysed in IP buffer: 1% Triton X-100 in PBS, 1× protease inhibitors (Roche) and Phospho stop (Roche) for 20 min on ice followed by centrifugation at 5000 rpm for 5 min at 4 °C. BCA assays were performed to quantify the amount of protein, and 500 μ g of protein was used for immunoprecipitations. 2 μ g anti-V5 antibody was added to the cell lysate and incubated on a wheel rotator overnight at 4 °C. On the following day, Protein G dynabeads (Invitrogen) were added to the samples and incubated for a further 3 h on the wheel at 4 °C. Beads were washed three times for 5 min each using the IP buffer followed by addition of 2× sample buffer containing DTT (1 mM final). Samples were heated at 95 °C for 5 min, loaded on 4-12% Novex Bis-tris gels (Invitrogen), and migrated for 1.5 h at 150 V followed by western blotting. Immunoprecipitations were performed by adding 2 μ g of POM2 antibody to 500 μ l of cell medium and incubating overnight on a wheel rotator at 4 °C. Protein G beads were then added, and incubation on a wheel rotator at 4 °C was performed again. RNA isolation and quantitative PCR. RNA extraction and quantitative PCR were performed as described previously 1 . The following primers were used: EGR2 forward: 5′-AATGGCTTGGGACTGACTTG-3′; EGR2 reverse: 5′-GCCAGAGAAACCTCCATT-3′; GAPDH forward: 5′-CCACCCCAGCA AGGAGAC-3′; GAPDH reverse: 5′ -GAAATTGTGAGGGAGATGCT-3′ . Zebrafish mutant strains and analysis. Adult zebrafish were maintained in the Washington University Zebrafish Consortium facility (http://zebrafishfacility. wustl.edu/) and all experiments were performed in compliance with institutional protocols. Embryos were collected from harem matings or in vitro fertilization, raised at 28.5 °C, and staged according to standard protocols 27 . The gpr126 st49 and gpr126 st63 mutants were described previously 7, 8 . Zebrafish peptide treatment, immunostaining, and quantification. gpr126 st63 or gpr126 st49 mutants were collected from homozygous mutant crosses and wildtype larvae were collected from AB* strain crosses and raised to 50 hpf. FT treatment of gpr126 mutants was performed as previously described 15 . Briefly, egg water was replaced with either 20 μ M FT in egg water or egg water containing an equivalent volume of DMSO. At 55 hpf, larvae were washed twice and raised in egg water to 5 dpf. Wild-type and gpr126 larvae were fixed in 2% paraformaldehyde plus 1% tricholoroacetic acid in phosphate buffered saline, and Mbp and acetylated tubulin immunostaining was performed as described previously 8, 28 . Expression scoring was performed with observers blinded to treatment according to the following rubric: strong, strong and consistent expression throughout PLLn; some, weak but consistent expression in PLLn; weak, weak and patchy expression in PLLn; none, no expression in PLLn. n = three independent replicate gpr126 st63 assays and one gpr126 st49 assay. n = 87 DMSO-treated gpr126 st63 larvae, 81 Prp-FT-treated gpr126 st63 larvae, 27 DMSO-treated gpr126 st49 larvae, 25 Prp-FT-treated gpr126 st49 larvae. Fluorescent nerve images were analysed using the Fiji software 29 . A rectangular region-of-interest (ROI) was drawn longitudinally over the fluorescent nerve. The longitudinal grey-scale histogram of the myelin basic protein (Mbp) was normalized pixel-by-pixel to the corresponding intensity of the acetylated tubulin (AcTub). The size of the measured ROIs was kept constant across different treatment modalities.
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Flow cytometry. SW10 cells were grown in P75 flasks at 50% density, rinsed with PBS, and detached from culture flasks with dissociation buffer containing EDTA (GIBCO). After detaching, cells were washed to remove residual EDTA and counted using a Neubauer chamber. Batches of 10 5 SW10 cells were transferred to FACS tubes, treated with HA-tagged recombinant peptides for 20 min, washed, and incubated with Alexa-488 conjugated anti-HA antibody for 30 min. After further washes and centrifugations, cells were resuspended in 200 μ l FACS buffer (PBS + 10% FBS) and analysed with a FACS Canto II cytofluorimeter (BD Biosciences). Data were analysed using FloJo software. Western blot analysis. Schwann cells were lysed in cell-lysis buffer (Tris-HCl 20 mM, NaCl 137 mM, Triton-X-100 1%) supplemented with protease inhibitor cocktail (Roche complete mini). The lysate was homogenized by passing several times through a 26G syringe, and cleared by centrifugation at 8,000g, 4 °C for 2 min. in a tabletop centrifuge (Eppendorf 5415R). Protein concentration was measured with the BCA assay (Thermo Scientific). 10 μ g total protein was boiled in 4 × LDS (Invitrogen) at 95 °C for 5 min. After a short centrifugation, samples were loaded on a gradient of 4-12% Novex Bis-Tris Gel (Invitrogen) for electrophoresis at constant voltage of 200 V. Gels were transferred to PVDF membranes with the iBlot system (Life technologies). Membranes were blocked with 5% Top-Block (Sigma) in PBS-T for 1h at room temperature. Primary antibody was incubated overnight in PBS-T with 5% Top-Block. Membranes were washed three times with PBS-T for 10 min and incubated for 1 h with secondary antibodies coupled to horseradish peroxidase at room temperature. After three washes with PBS-T, the membranes were developed with a Crescendo chemiluminescence substrate system (Millipore). Signals were detected using a Stella 3200 imaging system (Raytest).
Antibodies. Monoclonal antibodies against PrP
C were obtained and used as described previously 4 . Fab3 and Fab71 antibodies were generated using the phage display technology and their epitopes were mapped with overlapping peptides. Anti AKT, p-AKT were obtained from Cell signaling and used at 1:2,000 dilutions for western blotting. The anti-p75NGF receptor antibody was obtained from Abcam and used at a 1:200 dilution for immunofluorescence. Anti V5 antibody was from Invitrogen and used at a dilution of 1:500 for western blot and 2 μ g antibody was used for immunoprecipitation on 500 μ g of cell lysate. Cyclic AMP measurements. In the direct cAMP ELISA assay, cAMP levels were assessed with a colorimetric competitive immunoassay (Enzo Life Sciences). Quantitative determination of intracellular cAMP was performed in cells or tissues lysed in 0.1 M HCl to stop endogenous phosphodiesterase activity and to stabilize the released cAMP. SW10 or HEK293T cells (100,000 cells per well) were plated in 6-well plates to ~ 50% density. Cells were treated with conditioned medium or recombinant peptides (2 μ M, unless specified) for 20 min unless otherwise mentioned. Cells were lysed with 0.1 M HCl lysis buffer (Direct cAMP ELISA kit, Enzo). To ensure complete detachment of cells, cell scrapers were used. Lysates were homogenized with a 26G needle and syringe before clearing by centrifugation at 600g for 10 min. The subsequent steps were performed according to the manufacturer's protocol based on competition of sample cAMP with a cAMP-alkaline phosphatase conjugate. To measure in vivo cAMP changes, BL6, Prnp ZH3/ZH3 or Prnp ZH1/ZH1 mice were intravenously injected with 600 μ g of either FT or, as a control, uncharged FT (   −   →   FT 23 50 K A ). Twenty minutes after infusion, mice were killed and all organs were collected. For cAMP assays, organs were homogenized in 0.1 M HCl. Subsequent steps were performed according to the manufacturer's protocols as described above. Cyclic AMP levels were calculated using a cAMP standard curve in the case of ELISA based assay. Finally, cAMP concentrations were normalized to total protein content in each sample. cAMP changes are represented as fold changes to the respective controls. For each experiment, at least three independent biological replicates were used. For in vivo assays, groups of 8-16 mice were used for each experiment. For normalization purposes, the median value of the respective control sample was defined as 1. All measurements within each panel were normalized to this control value. For in vivo assays, sample sets were coded and investigators were blinded to their identities. The assignment of codes to sample identities was performed only after the cAMP values were plotted for each set. Generation of Schwann cell lines devoid of Gpr126. We designed two CRISPR short-guide RNA (sgRNAs) against exon 2 of Gpr126 (upper Guide CCTGTGTTCCTCTCTCAGGT and lower Guide AACAGGAACAGCAGG GCGCT). The DNA sequences corresponding to the sgRNAs were cloned into expression plasmids and transfected with EGFP-expressing Cas9-nickase plasmids. Single EGFP-expressing Schwann cells were isolated with a FACS sorter (Aria III). To determine the exact sequence of indels induced by genome editing, we amplified the sgRNA-targeted locus by PCR and subcloned the fragments into blunt-TOPO vectors. Ten colonies per cell line were sequenced and showed distinct indels on each allele. A clonal subline devoid of Gpr126 was used for further studies. This cell line possessed insertions on both the alleles; a 49-bp insertion at position 118 and a 5-bp insertion at position 84 on each allele. Both insertions led to a frameshift and to the generation of premature stop codons leading to early translation termination. Promoter luciferase assay. Luciferase reporter constructs were generated containing a 1.3-kB sequence upstream of the transcription-starting site of Egr2. SW10 Schwann cells were transfected with Egr2 reporter construct and a renilla plasmid using lipofectamine 2000. After one day in vitro, Schwann cells were treated with recombinant full-length PrP , the globular domain of PrP (121-231) or PBS control. Luciferase activity was measured 24 h after stimulation with Dual-Luciferase Reporter Assay System (Promega) according to the manufacturer's recommendations. Results were normalized to renilla transfection controls. Immunocytochemistry. Glass coverslips were placed in 12-well plates (Thermo Scientific) and coated with 0.01% w/v Poly-l-lysine solution (Sigma) overnight at room temperature. Coverslips were washed three times with ddH 2 O and dried for 2 h in a laminar-flow hood. Schwann cells were seeded and cultured at 50% density. Cells were treated with recombinant FT-PrP, full length recPrP or C1-PrP for 20 min, and washed with serum-free DMEM. Cells were further washed with PBS followed by fixation with 4% paraformaldehyde. Fixed cells were incubated in blocking buffer (PBS+ 10% FBS) for 1 h. Cells were treated with various primary antibodies followed by washes and incubation with Alexa 488 and Alexa 647 tagged rabbit or mouse secondary antibodies (Life Technologies). Imaging was performed by Leica SP2 confocal microscope using a 20× objective; images were processed by Image J software. Transmission electron microscopy. Transmission electron microscopy was performed as previously described 6 . Briefly, mice under deep anaesthesia were subjected to transcardial perfusion with PBS heparin and sciatic nerves were fixed in situ with 2.5% glutaraldehyde plus 2% paraformaldehyde in 0.1 M phosphate buffer, pH 7.4 and embedded in Epon. Ultrathin sections were mounted on copper grids coated with Formvar membrane and contrasted with uranyl acetate/lead citrate. Micrographs were acquired using a Hitachi H-7650 electron microscope (Hitachi High-Tech, Japan) operating at 80 kV. Brightness and contrast were adjusted using Photoshop. For quantification of Remak bundles and onion bulblike structures, images were captured at 1,500× magnification and axon numbers and abnormal onion bulb-like structures were counted manually. Quantification was performed in a blinded fashion by assigning numbers to the images and upon completion of quantification genotypes were revealed. Recombinant peptides. HA-tagged and untagged synthetic peptides were produced by EZ Biosciences. A stock solution of 2 mM was prepared by dissolving the peptides in PBS and they were used at a final concentration of 2 μ M unless specified. The sequences of all the peptides used in this study can be found in Extended Data Table 1 .
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Extended Data Figure 1 | FT binds to Schwann cells through a proteinaceous receptor. a, Primary Schwann cells were isolated from the sciatic nerves of Prnp ZH1/ZH1 mice and grown on coverslips. Cells were exposed for 20 min to recombinant PrP C , FT, or GD (2 μ M), fixed, and stained with POM2 (FT, PrP C ) or POM1 (GD). Antibodies were visualized in the green channel and nuclei were stained with DAPI (blue). PrP C and FT, but not GD, adhered to the cells. Scale bars, 25 μ m. b, Schematic representation of the target region for transcription activatorlike endonucleases (TALEN) in the Prnp gene. Target guides are indicated by arrows. Gene editing resulted in a deletion leading to a frame shift in the PrP C coding sequence (designated as a conflict in the figure) and a premature stop codon identified by sequencing. c, Wild-type SW10 cells and a subclone isolated after treatment with TALEN (SW10 ∆PrP ) were probed by western blotting using POM1. SW10 ∆PrP showed complete abrogation of PrP C expression and was used for further experiments. Levels of actin on the same membrane were monitored to confirm equal loading of cell lysates onto the gel. ) . Cell medium was collected 48 h after transfection and subjected to immunoprecipitation with monoclonal antibody POM2 (against PrP C ), followed by western blotting using biotinylated POM2 and streptavidin-HRP. FT was observed only in the medium from HEK PrP cells. b, FT released into the conditioned medium of HEK PrP was immunoprecipitated using POM2 and visualized by western blotting with biotinylated POM2. Various amounts of recombinant FT (3.125-100 ng) were used for calibration, and the concentration of FT released into 1 ml of the medium upon immunoprecipitation was estimated to be 37 ng ml −1 . c, Conditioned medium from primary BL6 Schwann cells cultures (PSC BL6 ) was subjected to immunoprecipitation with antibody POM2 followed by western blotting with POM2. For control, we used conditioned medium from HEK cells transfected with a non-coding plasmid (HEK empty ) or a with a plasmid encoding murine PrP C (HEK PrP ). FT was detected only in conditioned medium from HEK PrP cells (lane 2) but not in conditioned medium from two independent PSC BL6 cultures (lanes 3 and 4). Asterisks denote immunoglobulins detected by the secondary antibody. d, Sciatic nerve lysates obtained from 10-week-old Prnp
and BL6 mice and subjected to immunoprecipitation with POM2 antibody followed by western blotting with POM2. Full-length PrP C , but no FT, was detectable in the immunoprecipitates of nerves from BL6 mice. e, Wildtype HEK293T cells (HEK WT ) or HEK293T cells overexpressing various GPCRs bearing V5 epitope tags (HEK Gpr126 , HEK Gpr124 , and HEK Gpr176 ) were grown on coverslips and stained with anti V5 antibody (detecting tagged GPCRs; magenta). Nuclei were stained with DAPI (blue). Staining revealed cell surface expression of all transfected GPCRs. Scale bar, 8 μ m. f, HA-tagged FT peptide (2 μ M) was added to HEK WT cells or to HEK GPR126 cells, labelled with anti-HA antibody, and subjected to cytofluorimetry. Overexpression of Gpr126 increased the binding of FT . g, Binding of HA-tagged FT to HEK GPR126 cells (right, monitored by cytofluorimetry) was conspicuously increased over that of wild-type, Gpr176, and Gpr124-overexpressing HEK293T cells. Data are representative of three biologically independent experiments; statistical significance was evaluated by unpaired Student's t-test. Error bars show s.e.m. . HEK PrP were optionally treated with 100 μ M of the TAPI-2 protease inhibitor for 24 h before harvesting the medium. TAPI-2 treatment resulted in reduced cAMP induction, suggesting that impaired proteolytic cleavage of the FT from PrP C resulted in decreased signalling. d, Quantification of FT released into the medium relative to the total amount of PrP C in lysates by western blotting. The spent medium of HEK PrP cells treated with TAPI-2 contained less FT. e, SW10 and SW10 ∆Gpr126 cells were transfected with an Egr2-controlled firefly luciferase reporter and treated with recombinant FT (2 μ M) or PBS (24 h). Ordinate: luciferase expression normalized to a renilla luciferase control (n = 3; * P < 0.05; t-test). Luciferase activity was observed only in SW10 cells stimulated with FT but not in SW10 ∆Gpr126 cells. f, Primary Schwann cells were exposed to recombinant FT (2 μ M, 1 h) or PBS. Egr2 mRNA expression was measured by quantitative RT-PCR and normalized against a panel of housekeeping genes. For uncropped gels, see Supplementary Information File 1. g, SW10 ∆PrP and SW10 ∆Gpr126 cells were grown in 6-well plates, exposed to recombinant FT (≤ 30 min), and analysed by western blotting (left). Densitometry (right) showed increased phospho-AKT/AKT ratio in SW10 ∆PrP cells, but not in SW10 ∆Gpr126 cells. Data are representative of three biologically independent experiments; statistical significance was evaluated by unpaired Student's t-test. Error bars show s.e.m.
